Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 5,698 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 5,698 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $24.31, for a total value of $138,518.38. Following the transaction, the chief executive officer now owns 1,496,729 shares in the company, valued at approximately $36,385,481.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tyra Biosciences Price Performance

TYRA stock opened at $24.36 on Friday. Tyra Biosciences, Inc. has a 1 year low of $10.38 and a 1 year high of $25.14. The firm has a market capitalization of $1.28 billion, a P/E ratio of -14.50 and a beta of 1.01. The business’s 50-day moving average is $21.29 and its two-hundred day moving average is $18.73.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. On average, analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Piper Sandler initiated coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research note on Thursday, August 8th. Oppenheimer increased their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $26.40.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Tyra Biosciences by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after purchasing an additional 8,324 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after purchasing an additional 14,352 shares during the last quarter. HighVista Strategies LLC acquired a new stake in shares of Tyra Biosciences in the 2nd quarter valued at about $257,000. Finally, Victory Capital Management Inc. grew its stake in Tyra Biosciences by 53.4% during the 4th quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock worth $696,000 after buying an additional 17,490 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.